POINT Biopharma Global Inc.

POINT Biopharma Global Inc. entered the public markets through a de-SPAC merger with Research Alliance Corp. I, which traded on Nasdaq under the ticker RACA. The transaction closed in 2021, establishing POINT Biopharma as a publicly listed radiopharmaceutical company focused on the development of targeted cancer therapies, operating within the healthcare and life sciences sector. The company filed an 8-K with the Securities and Exchange Commission on June 5, 2023, representing a material corporate disclosure during its post-merger operating phase. Research Alliance Corp. I completed its blank-check IPO in 2021 with a mandate targeting healthcare innovation. Sign up at SpacDesk for full filing history, deal analytics, and real-time SPAC data coverage.